An Angiopep2-PAPTP Construct Overcomes the Blood-Brain Barrier. New Perspectives against Brain Tumors
A developing family of chemotherapeutics—derived from 5-(4-phenoxybutoxy)psoralen (PAP-1)—target mitochondrial potassium channel mtKv1.3 to selectively induce oxidative stress and death of diseased cells. The key to their effectiveness is the presence of a positively charged triphenylphosphonium gro...
Main Authors: | Sofia Parrasia, Andrea Rossa, Tatiana Varanita, Vanessa Checchetto, Riccardo De Lorenzi, Mario Zoratti, Cristina Paradisi, Paolo Ruzza, Andrea Mattarei, Ildikò Szabò, Lucia Biasutto |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2021-02-01
|
Series: | Pharmaceuticals |
Subjects: | |
Online Access: | https://www.mdpi.com/1424-8247/14/2/129 |
Similar Items
-
Angiopep-2-Modified Nanoparticles for Brain-Directed Delivery of Therapeutics: A Review
by: Saffiya Habib, et al.
Published: (2022-02-01) -
Recombinant expressing angiopep-2 fused anti-VEGF single chain Fab (scFab) could cross blood–brain barrier and target glioma
by: Xuemei Ji, et al.
Published: (2019-10-01) -
Specific anti‐glioma targeted‐delivery strategy of engineered small extracellular vesicles dual‐functionalised by Angiopep‐2 and TAT peptides
by: Zhanchi Zhu, et al.
Published: (2022-08-01) -
DA7R: A 7-Letter Zip Code to Target PDAC
by: Sofia Parrasia, et al.
Published: (2023-05-01) -
Angiopep-2-conjugated poly(ethylene glycol)-co-poly(ε-caprolactone) polymersomes for dual-targeting drug delivery to glioma in rats
by: Lu F, et al.
Published: (2017-03-01)